Name: Global Adoptive Cellular Immunotherapy Market Insights and Forecast to 2035
Brand: Extent Research
Price: 3500 USD
Availability: InStock
Rating: 4.6 (236 reviews)

Global Adoptive Cellular Immunotherapy Market

Market Size in USD Billion

CAGR : 17.60%

USD 1.14

2025

USD 4.17

2033

Forecast Period	2025 - 2033
Market Size (Base Year)	USD 1.14 Billion
Market Size (Forecast)	USD 4.17 Billion
CAGR	17.60%
Major Market Players	Data provided in full report

Global Adoptive Cellular Immunotherapy Market report published by EXTENT RESEARCH exemplifies the market growth driving factors such as changing market dynamics, developmental trends, product launches, market sustainable strategies, and latest opportunities. The report also encompasses the market threats and business growth restraints to keep the readers updated on the market growth and status on the global platform. This market study owns the responsibility to offer in-depth business breakdown structure, changing market statistics, and competitive market aspects. Nevertheless, the pre- and post-COVID-19 market analysis is well sketched in the report to touch upon each and every market detail whether microscopic or macroscopic so as to enlighten the readers with the market practicalities and opportunities.

Data provided by Extent Research. Source: https://www.extentresearch.com/adoptive-cellular-immunotherapy-market

In the global Adoptive Cellular Immunotherapy report, the competitive section has all the information related to the company finances, growth aspects, business strategies, and future possibilities encrypted through the comprehensive company profiling. Company profiling is strategy used to gain better insight on to the company growth opportunities & challenges and economic stability in the long run. Some of the key market players dominating the global Adoptive Cellular Immunotherapy market mentioned in the report is: Amgen Inc, Autolus Therapeutics Plc, Beijing Immunochina Medical Science & Technology Co Ltd, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Co, bluebird bio Inc, CARsgen Therapeutics Ltd, Celgene Corp, Cell Medica Ltd, Cellular Biomedicine Group Inc, Celularity Inc, Celyad SA, Daiichi Sankyo Co Ltd, Fosun Pharmaceutical AG, Gilead Sciences Inc, Guangzhou Anjie Biomedical Technology Co Ltd, Hangzhou Converd Co Ltd, Hebei Senlang Biotechnology Inc Ltd, HRAIN Biotechnology Co Ltd, Juno Therapeutics Inc, Kite Pharma Inc, Nanjing Legend Biotech Co Ltd, NantKwest Inc, Nkarta Inc, Novartis AG, Ono Pharmaceutical Co Ltd, Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, Sorrento Therapeutics Inc, Takara Bio Inc, .

In terms of geographical analysis, this report reveals the future of the Adoptive Cellular Immunotherapy market in different regions owing to its supply & demand ratio, sales & marketing, product demand, and market developmental trends. Some of the regions proving profitable for the market growth include: by Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

The global Adoptive Cellular Immunotherapy market report is here to shed light on the market competitive landscape, geographical distribution, market analysis & statistics, sales, distribution, and opportunities to systematically comprehend the complete market study.

Segmentation of the Global Adoptive Cellular Immunotherapy Market:

Product type

TIL, LAK, CAR-T, TCR-T, CIK, NK, DC, Other,

by Application

Hospital, Cancer Hospital, Centers for Disease Control and Prevention, Rehabilitation Center, Other,

Why Purchase Global Adoptive Cellular Immunotherapy Market report?

Analysis on market dynamics, company profiling, and regional distribution
Adoptive Cellular Immunotherapy market study focuses on the key business strategies and growth targets
Study on changing market behaviors related to latest opportunities & challenges
Global Adoptive Cellular Immunotherapy market study clearly explains the market statistics and business breakdown structure
Availability of market customization and 24*7 services to offer complete market analysis

Report Scope and Market Segmentation

ATTRIBUTES	Global Adoptive Cellular Immunotherapy Market KEY MARKET INSIGHTS
Segments Covered	By Product Type: All Products Type Includes By Application: All Application Type Includes By End User: All End User Type Includes By Distribution Channel: All Distribution Channel Includes
Countries Covered	North America U.S., Canada, Mexico Europe Germany, United Kingdom, France, Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe Asia-Pacific China, India, Japan, New Zealand, South Korea, Australia, Southeast Asia, Rest of Asia Pacific Latin America Brazil, Argentina, Rest of Latin America Middle East & Africa Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa
Key Market Players	Leading Tier 1 Corporations Prominent Regional Manufacturers Emerging Market Disruptors Technology Integrators & Suppliers *Complete vendor layout of 15+ major players provided in the final report.
Market Opportunities	Market Size and Growth: Quantifying the total addressable market (TAM) and projected growth rates to assess financial viability. Customer Segmentation: Identifying target audience behaviors, pain points, and specific unfulfilled demands. Competitive Landscape: Analyzing existing competitors' strengths, weaknesses, and market share to pinpoint gaps and opportunities. Industry Trends: Mapping technological, regulatory, and economic shifts that create favorable conditions for market entry. Risk Assessment: Evaluating barriers to entry and operational challenges alongside strategic roadmaps for mitigation.
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by our expert team also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.

Meet the Team

Julie

Author

Julie Jayne is a distinguished multidisciplinary strategist and the Head of Research at Extent Research, where she leverages over a decade of comprehensive experience in the global market intelligence industry. Backed by a robust academic foundation that includes a B.Sc. and an MBA, she perfectly...

Priya M

Reviewed By

With over 14 years of dedicated professional expertise in business-to-business (B2B) intelligence, Priya M stands as a distinguished leader in corporate strategy, revenue growth, and advanced data analysis. Her dynamic career is defined by a relentless focus on mitigating business risks and empowering corporate executives...

Learn more about Priya M

BASIC ATTRIBUTES \| KEY MARKET INSIGHTS
Report Title	Global Adoptive Cellular Immunotherapy Market
Base Year	2025
Forecast Period	2025 - 2033
Market Size (Base)	USD 1.14 Billion
Projected Size	USD 4.17 Billion
CAGR	17.60%

                            1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Adoptive Cellular Immunotherapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2035
        1.2.2 TIL
        1.2.3 LAK
        1.2.4 CAR-T
        1.2.5 TCR-T
        1.2.6 CIK
        1.2.7 NK
        1.2.8 DC
        1.2.9 Other
    1.3 Market by Application
        1.3.1 Global Adoptive Cellular Immunotherapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2035
        1.3.2 Hospital
        1.3.3 Cancer Hospital
        1.3.4 Centers for Disease Control and Prevention
        1.3.5 Rehabilitation Center
        1.3.6 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Adoptive Cellular Immunotherapy Market Perspective (2017-2035)
    2.2 Adoptive Cellular Immunotherapy Growth Trends by Region
        2.2.1 Adoptive Cellular Immunotherapy Market Size by Region: 2017 VS 2021 VS 2035
        2.2.2 Adoptive Cellular Immunotherapy Historic Market Size by Region (2017-2022)
        2.2.3 Adoptive Cellular Immunotherapy Forecasted Market Size by Region (2023-2035)
    2.3 Adoptive Cellular Immunotherapy Market Dynamics
        2.3.1 Adoptive Cellular Immunotherapy Industry Trends
        2.3.2 Adoptive Cellular Immunotherapy Market Drivers
        2.3.3 Adoptive Cellular Immunotherapy Market Challenges
        2.3.4 Adoptive Cellular Immunotherapy Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Adoptive Cellular Immunotherapy Players by Revenue
        3.1.1 Global Top Adoptive Cellular Immunotherapy Players by Revenue (2017-2022)
        3.1.2 Global Adoptive Cellular Immunotherapy Revenue Market Share by Players (2017-2022)
    3.2 Global Adoptive Cellular Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Adoptive Cellular Immunotherapy Revenue
    3.4 Global Adoptive Cellular Immunotherapy Market Concentration Ratio
        3.4.1 Global Adoptive Cellular Immunotherapy Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Adoptive Cellular Immunotherapy Revenue in 2021
    3.5 Adoptive Cellular Immunotherapy Key Players Head office and Area Served
    3.6 Key Players Adoptive Cellular Immunotherapy Product Solution and Service
    3.7 Date of Enter into Adoptive Cellular Immunotherapy Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Adoptive Cellular Immunotherapy Breakdown Data by Type
    4.1 Global Adoptive Cellular Immunotherapy Historic Market Size by Type (2017-2022)
    4.2 Global Adoptive Cellular Immunotherapy Forecasted Market Size by Type (2023-2035)
5 Adoptive Cellular Immunotherapy Breakdown Data by Application
    5.1 Global Adoptive Cellular Immunotherapy Historic Market Size by Application (2017-2022)
    5.2 Global Adoptive Cellular Immunotherapy Forecasted Market Size by Application (2023-2035)
6 North America
    6.1 North America Adoptive Cellular Immunotherapy Market Size (2017-2035)
    6.2 North America Adoptive Cellular Immunotherapy Market Size by Type
        6.2.1 North America Adoptive Cellular Immunotherapy Market Size by Type (2017-2022)
        6.2.2 North America Adoptive Cellular Immunotherapy Market Size by Type (2023-2035)
        6.2.3 North America Adoptive Cellular Immunotherapy Market Share by Type (2017-2035)
    6.3 North America Adoptive Cellular Immunotherapy Market Size by Application
        6.3.1 North America Adoptive Cellular Immunotherapy Market Size by Application (2017-2022)
        6.3.2 North America Adoptive Cellular Immunotherapy Market Size by Application (2023-2035)
        6.3.3 North America Adoptive Cellular Immunotherapy Market Share by Application (2017-2035)
    6.4 North America Adoptive Cellular Immunotherapy Market Size by Country
        6.4.1 North America Adoptive Cellular Immunotherapy Market Size by Country (2017-2022)
        6.4.2 North America Adoptive Cellular Immunotherapy Market Size by Country (2023-2035)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Adoptive Cellular Immunotherapy Market Size (2017-2035)
    7.2 Europe Adoptive Cellular Immunotherapy Market Size by Type
        7.2.1 Europe Adoptive Cellular Immunotherapy Market Size by Type (2017-2022)
        7.2.2 Europe Adoptive Cellular Immunotherapy Market Size by Type (2023-2035)
        7.2.3 Europe Adoptive Cellular Immunotherapy Market Share by Type (2017-2035)
    7.3 Europe Adoptive Cellular Immunotherapy Market Size by Application
        7.3.1 Europe Adoptive Cellular Immunotherapy Market Size by Application (2017-2022)
        7.3.2 Europe Adoptive Cellular Immunotherapy Market Size by Application (2023-2035)
        7.3.3 Europe Adoptive Cellular Immunotherapy Market Share by Application (2017-2035)
    7.4 Europe Adoptive Cellular Immunotherapy Market Size by Country
        7.4.1 Europe Adoptive Cellular Immunotherapy Market Size by Country (2017-2022)
        7.4.2 Europe Adoptive Cellular Immunotherapy Market Size by Country (2023-2035)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Adoptive Cellular Immunotherapy Market Size (2017-2035)
    8.2 Asia-Pacific Adoptive Cellular Immunotherapy Market Size by Type
        8.2.1 Asia-Pacific Adoptive Cellular Immunotherapy Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Adoptive Cellular Immunotherapy Market Size by Type (2023-2035)
        8.2.3 Asia-Pacific Adoptive Cellular Immunotherapy Market Share by Type (2017-2035)
    8.3 Asia-Pacific Adoptive Cellular Immunotherapy Market Size by Application
        8.3.1 Asia-Pacific Adoptive Cellular Immunotherapy Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Adoptive Cellular Immunotherapy Market Size by Application (2023-2035)
        8.3.3 Asia-Pacific Adoptive Cellular Immunotherapy Market Share by Application (2017-2035)
    8.4 Asia-Pacific Adoptive Cellular Immunotherapy Market Size by Region
        8.4.1 Asia-Pacific Adoptive Cellular Immunotherapy Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Adoptive Cellular Immunotherapy Market Size by Region (2023-2035)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Adoptive Cellular Immunotherapy Market Size (2017-2035)
    9.2 Latin America Adoptive Cellular Immunotherapy Market Size by Type
        9.2.1 Latin America Adoptive Cellular Immunotherapy Market Size by Type (2017-2022)
        9.2.2 Latin America Adoptive Cellular Immunotherapy Market Size by Type (2023-2035)
        9.2.3 Latin America Adoptive Cellular Immunotherapy Market Share by Type (2017-2035)
    9.3 Latin America Adoptive Cellular Immunotherapy Market Size by Application
        9.3.1 Latin America Adoptive Cellular Immunotherapy Market Size by Application (2017-2022)
        9.3.2 Latin America Adoptive Cellular Immunotherapy Market Size by Application (2023-2035)
        9.3.3 Latin America Adoptive Cellular Immunotherapy Market Share by Application (2017-2035)
    9.4 Latin America Adoptive Cellular Immunotherapy Market Size by Country
        9.4.1 Latin America Adoptive Cellular Immunotherapy Market Size by Country (2017-2022)
        9.4.2 Latin America Adoptive Cellular Immunotherapy Market Size by Country (2023-2035)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Adoptive Cellular Immunotherapy Market Size (2017-2035)
    10.2 Middle East & Africa Adoptive Cellular Immunotherapy Market Size by Type
        10.2.1 Middle East & Africa Adoptive Cellular Immunotherapy Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Adoptive Cellular Immunotherapy Market Size by Type (2023-2035)
        10.2.3 Middle East & Africa Adoptive Cellular Immunotherapy Market Share by Type (2017-2035)
    10.3 Middle East & Africa Adoptive Cellular Immunotherapy Market Size by Application
        10.3.1 Middle East & Africa Adoptive Cellular Immunotherapy Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Adoptive Cellular Immunotherapy Market Size by Application (2023-2035)
        10.3.3 Middle East & Africa Adoptive Cellular Immunotherapy Market Share by Application (2017-2035)
    10.4 Middle East & Africa Adoptive Cellular Immunotherapy Market Size by Country
        10.4.1 Middle East & Africa Adoptive Cellular Immunotherapy Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Adoptive Cellular Immunotherapy Market Size by Country (2023-2035)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Amgen Inc
        11.1.1 Amgen Inc Company Details
        11.1.2 Amgen Inc Business Overview
        11.1.3 Amgen Inc Adoptive Cellular Immunotherapy Introduction
        11.1.4 Amgen Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.1.5 Amgen Inc Recent Developments
    11.2 Autolus Therapeutics Plc
        11.2.1 Autolus Therapeutics Plc Company Details
        11.2.2 Autolus Therapeutics Plc Business Overview
        11.2.3 Autolus Therapeutics Plc Adoptive Cellular Immunotherapy Introduction
        11.2.4 Autolus Therapeutics Plc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.2.5 Autolus Therapeutics Plc Recent Developments
    11.3 Beijing Immunochina Medical Science & Technology Co Ltd
        11.3.1 Beijing Immunochina Medical Science & Technology Co Ltd Company Details
        11.3.2 Beijing Immunochina Medical Science & Technology Co Ltd Business Overview
        11.3.3 Beijing Immunochina Medical Science & Technology Co Ltd Adoptive Cellular Immunotherapy Introduction
        11.3.4 Beijing Immunochina Medical Science & Technology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.3.5 Beijing Immunochina Medical Science & Technology Co Ltd Recent Developments
    11.4 Bellicum Pharmaceuticals Inc
        11.4.1 Bellicum Pharmaceuticals Inc Company Details
        11.4.2 Bellicum Pharmaceuticals Inc Business Overview
        11.4.3 Bellicum Pharmaceuticals Inc Adoptive Cellular Immunotherapy Introduction
        11.4.4 Bellicum Pharmaceuticals Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.4.5 Bellicum Pharmaceuticals Inc Recent Developments
    11.5 Bristol-Myers Squibb Co
        11.5.1 Bristol-Myers Squibb Co Company Details
        11.5.2 Bristol-Myers Squibb Co Business Overview
        11.5.3 Bristol-Myers Squibb Co Adoptive Cellular Immunotherapy Introduction
        11.5.4 Bristol-Myers Squibb Co Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.5.5 Bristol-Myers Squibb Co Recent Developments
    11.6 bluebird bio Inc
        11.6.1 bluebird bio Inc Company Details
        11.6.2 bluebird bio Inc Business Overview
        11.6.3 bluebird bio Inc Adoptive Cellular Immunotherapy Introduction
        11.6.4 bluebird bio Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.6.5 bluebird bio Inc Recent Developments
    11.7 CARsgen Therapeutics Ltd
        11.7.1 CARsgen Therapeutics Ltd Company Details
        11.7.2 CARsgen Therapeutics Ltd Business Overview
        11.7.3 CARsgen Therapeutics Ltd Adoptive Cellular Immunotherapy Introduction
        11.7.4 CARsgen Therapeutics Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.7.5 CARsgen Therapeutics Ltd Recent Developments
    11.8 Celgene Corp
        11.8.1 Celgene Corp Company Details
        11.8.2 Celgene Corp Business Overview
        11.8.3 Celgene Corp Adoptive Cellular Immunotherapy Introduction
        11.8.4 Celgene Corp Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.8.5 Celgene Corp Recent Developments
    11.9 Cell Medica Ltd
        11.9.1 Cell Medica Ltd Company Details
        11.9.2 Cell Medica Ltd Business Overview
        11.9.3 Cell Medica Ltd Adoptive Cellular Immunotherapy Introduction
        11.9.4 Cell Medica Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.9.5 Cell Medica Ltd Recent Developments
    11.10 Cellular Biomedicine Group Inc
        11.10.1 Cellular Biomedicine Group Inc Company Details
        11.10.2 Cellular Biomedicine Group Inc Business Overview
        11.10.3 Cellular Biomedicine Group Inc Adoptive Cellular Immunotherapy Introduction
        11.10.4 Cellular Biomedicine Group Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.10.5 Cellular Biomedicine Group Inc Recent Developments
    11.11 Celularity Inc
        11.11.1 Celularity Inc Company Details
        11.11.2 Celularity Inc Business Overview
        11.11.3 Celularity Inc Adoptive Cellular Immunotherapy Introduction
        11.11.4 Celularity Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.11.5 Celularity Inc Recent Developments
    11.12 Celyad SA
        11.12.1 Celyad SA Company Details
        11.12.2 Celyad SA Business Overview
        11.12.3 Celyad SA Adoptive Cellular Immunotherapy Introduction
        11.12.4 Celyad SA Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.12.5 Celyad SA Recent Developments
    11.13 Daiichi Sankyo Co Ltd
        11.13.1 Daiichi Sankyo Co Ltd Company Details
        11.13.2 Daiichi Sankyo Co Ltd Business Overview
        11.13.3 Daiichi Sankyo Co Ltd Adoptive Cellular Immunotherapy Introduction
        11.13.4 Daiichi Sankyo Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.13.5 Daiichi Sankyo Co Ltd Recent Developments
    11.14 Fosun Pharmaceutical AG
        11.14.1 Fosun Pharmaceutical AG Company Details
        11.14.2 Fosun Pharmaceutical AG Business Overview
        11.14.3 Fosun Pharmaceutical AG Adoptive Cellular Immunotherapy Introduction
        11.14.4 Fosun Pharmaceutical AG Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.14.5 Fosun Pharmaceutical AG Recent Developments
    11.15 Gilead Sciences Inc
        11.15.1 Gilead Sciences Inc Company Details
        11.15.2 Gilead Sciences Inc Business Overview
        11.15.3 Gilead Sciences Inc Adoptive Cellular Immunotherapy Introduction
        11.15.4 Gilead Sciences Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.15.5 Gilead Sciences Inc Recent Developments
    11.16 Guangzhou Anjie Biomedical Technology Co Ltd
        11.16.1 Guangzhou Anjie Biomedical Technology Co Ltd Company Details
        11.16.2 Guangzhou Anjie Biomedical Technology Co Ltd Business Overview
        11.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Adoptive Cellular Immunotherapy Introduction
        11.16.4 Guangzhou Anjie Biomedical Technology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.16.5 Guangzhou Anjie Biomedical Technology Co Ltd Recent Developments
    11.17 Hangzhou Converd Co Ltd
        11.17.1 Hangzhou Converd Co Ltd Company Details
        11.17.2 Hangzhou Converd Co Ltd Business Overview
        11.17.3 Hangzhou Converd Co Ltd Adoptive Cellular Immunotherapy Introduction
        11.17.4 Hangzhou Converd Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.17.5 Hangzhou Converd Co Ltd Recent Developments
    11.18 Hebei Senlang Biotechnology Inc Ltd
        11.18.1 Hebei Senlang Biotechnology Inc Ltd Company Details
        11.18.2 Hebei Senlang Biotechnology Inc Ltd Business Overview
        11.18.3 Hebei Senlang Biotechnology Inc Ltd Adoptive Cellular Immunotherapy Introduction
        11.18.4 Hebei Senlang Biotechnology Inc Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.18.5 Hebei Senlang Biotechnology Inc Ltd Recent Developments
    11.19 HRAIN Biotechnology Co Ltd
        11.19.1 HRAIN Biotechnology Co Ltd Company Details
        11.19.2 HRAIN Biotechnology Co Ltd Business Overview
        11.19.3 HRAIN Biotechnology Co Ltd Adoptive Cellular Immunotherapy Introduction
        11.19.4 HRAIN Biotechnology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.19.5 HRAIN Biotechnology Co Ltd Recent Developments
    11.20 Juno Therapeutics Inc
        11.20.1 Juno Therapeutics Inc Company Details
        11.20.2 Juno Therapeutics Inc Business Overview
        11.20.3 Juno Therapeutics Inc Adoptive Cellular Immunotherapy Introduction
        11.20.4 Juno Therapeutics Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.20.5 Juno Therapeutics Inc Recent Developments
    11.21 Kite Pharma Inc
        11.21.1 Kite Pharma Inc Company Details
        11.21.2 Kite Pharma Inc Business Overview
        11.21.3 Kite Pharma Inc Adoptive Cellular Immunotherapy Introduction
        11.21.4 Kite Pharma Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.21.5 Kite Pharma Inc Recent Developments
    11.22 Nanjing Legend Biotech Co Ltd
        11.22.1 Nanjing Legend Biotech Co Ltd Company Details
        11.22.2 Nanjing Legend Biotech Co Ltd Business Overview
        11.22.3 Nanjing Legend Biotech Co Ltd Adoptive Cellular Immunotherapy Introduction
        11.22.4 Nanjing Legend Biotech Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.22.5 Nanjing Legend Biotech Co Ltd Recent Developments
    11.23 NantKwest Inc
        11.23.1 NantKwest Inc Company Details
        11.23.2 NantKwest Inc Business Overview
        11.23.3 NantKwest Inc Adoptive Cellular Immunotherapy Introduction
        11.23.4 NantKwest Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.23.5 NantKwest Inc Recent Developments
    11.24 Nkarta Inc
        11.24.1 Nkarta Inc Company Details
        11.24.2 Nkarta Inc Business Overview
        11.24.3 Nkarta Inc Adoptive Cellular Immunotherapy Introduction
        11.24.4 Nkarta Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.24.5 Nkarta Inc Recent Developments
    11.25 Novartis AG
        11.25.1 Novartis AG Company Details
        11.25.2 Novartis AG Business Overview
        11.25.3 Novartis AG Adoptive Cellular Immunotherapy Introduction
        11.25.4 Novartis AG Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.25.5 Novartis AG Recent Developments
    11.26 Ono Pharmaceutical Co Ltd
        11.26.1 Ono Pharmaceutical Co Ltd Company Details
        11.26.2 Ono Pharmaceutical Co Ltd Business Overview
        11.26.3 Ono Pharmaceutical Co Ltd Adoptive Cellular Immunotherapy Introduction
        11.26.4 Ono Pharmaceutical Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.26.5 Ono Pharmaceutical Co Ltd Recent Developments
    11.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
        11.27.1 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Company Details
        11.27.2 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Business Overview
        11.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Adoptive Cellular Immunotherapy Introduction
        11.27.4 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.27.5 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Recent Developments
    11.28 Sorrento Therapeutics Inc
        11.28.1 Sorrento Therapeutics Inc Company Details
        11.28.2 Sorrento Therapeutics Inc Business Overview
        11.28.3 Sorrento Therapeutics Inc Adoptive Cellular Immunotherapy Introduction
        11.28.4 Sorrento Therapeutics Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.28.5 Sorrento Therapeutics Inc Recent Developments
    11.29 Takara Bio Inc
        11.29.1 Takara Bio Inc Company Details
        11.29.2 Takara Bio Inc Business Overview
        11.29.3 Takara Bio Inc Adoptive Cellular Immunotherapy Introduction
        11.29.4 Takara Bio Inc Revenue in Adoptive Cellular Immunotherapy Business (2017-2022)
        11.29.5 Takara Bio Inc Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer                        

Research Methodology

Data collection and base year analysis are done using proprietary data collection modules with large sample sizes. The process includes obtaining market information through extensive secondary sources, paid databases, and verifying data via primary (industry expert) validation.

Our market models include Vendor Positioning Grids, Market Timeline Analysis, Company Market Share Analysis, and Top-Down/Bottom-Up forecasting models. To know more about the research methodology, drop an inquiry to speak to our industry experts.

Speak to Analyst

Global Adoptive Cellular Immunotherapy Market